United Therapeutics (NASDAQ:UTHR) PT Raised to $400.00 at HC Wainwright

United Therapeutics (NASDAQ:UTHR) had its price objective upped by equities researchers at HC Wainwright from $300.00 to $400.00 in a research note issued on Thursday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 18.27% from the company’s previous close.

Other equities analysts have also recently issued research reports about the stock. Wells Fargo & Company increased their price objective on shares of United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 12th. TD Cowen increased their price objective on shares of United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. The Goldman Sachs Group increased their price objective on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Morgan Stanley cut shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price objective for the stock from $310.00 to $321.00 in a research report on Thursday, July 11th. Finally, StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 15th. Two research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $330.64.

United Therapeutics Stock Performance

Shares of UTHR opened at $338.22 on Thursday. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $15.00 billion, a P/E ratio of 15.99, a price-to-earnings-growth ratio of 1.45 and a beta of 0.55. The firm’s fifty day simple moving average is $303.01 and its two-hundred day simple moving average is $257.24. United Therapeutics has a 12 month low of $208.62 and a 12 month high of $343.98.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. The business had revenue of $677.70 million for the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The business’s quarterly revenue was up 33.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $4.86 earnings per share. As a group, analysts predict that United Therapeutics will post 24.87 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $258.09, for a total value of $929,124.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $33,551.70. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, Director Christopher Causey sold 2,240 shares of the stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $259.91, for a total transaction of $582,198.40. Following the completion of the transaction, the director now directly owns 4,185 shares of the company’s stock, valued at approximately $1,087,723.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $258.09, for a total transaction of $929,124.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $33,551.70. The disclosure for this sale can be found here. In the last 90 days, insiders sold 100,884 shares of company stock worth $29,622,803. Insiders own 12.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC boosted its holdings in United Therapeutics by 176.2% in the 1st quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock worth $3,288,000 after buying an additional 9,133 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in United Therapeutics by 19.0% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock worth $5,901,000 after buying an additional 4,100 shares during the period. International Assets Investment Management LLC boosted its holdings in United Therapeutics by 13,769.2% in the 4th quarter. International Assets Investment Management LLC now owns 9,015 shares of the biotechnology company’s stock worth $1,982,000 after buying an additional 8,950 shares during the period. DekaBank Deutsche Girozentrale boosted its holdings in United Therapeutics by 54.4% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 94,643 shares of the biotechnology company’s stock worth $20,617,000 after buying an additional 33,338 shares during the period. Finally, BNP Paribas Financial Markets boosted its holdings in United Therapeutics by 90.3% in the 4th quarter. BNP Paribas Financial Markets now owns 55,481 shares of the biotechnology company’s stock worth $12,200,000 after buying an additional 26,325 shares during the period. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.